Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Euclid Systems To Submit Ortho-K Contact Lens PMA For Overnight Wear

This article was originally published in The Gray Sheet

Executive Summary

Euclid Systems will submit a premarket approval application for the nighttime use of orthokeratology rigid gas-permeable extended wear (Ortho-K) contact lenses immediately upon completion of clinical data analysis, expected imminently.

You may also be interested in...



KeraVision Intacs Are Permanent, But Can Be Removed, FDA Concludes

Labeling for KeraVision's Intacs intrastromal corneal ring segments for treatment of mild myopia includes language indicating the reversible nature of the procedure. FDA approved the firm's August premarket approval application April 9.

Orthokeratology Lens Labeling Should Note Visual Improvement - Panel

Companies submitting premarket approval applications for rigid gas-permeable, extended-wear contact lenses for overnight orthokeratology (Ortho-K) should include in labeling a data grid showing the expected eyesight improvement likely to result from the process, FDA's Ophthalmology Devices Panel concluded at a Feb. 12 meeting in Rockville, Maryland.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel